logo

For the Inventor, By the Inventor

Cambridge, MA, United States of America

Lu Huang

This inventor holds 14 USPTO granted patents and 6 published patent applications and 4 EPO patents, primarily in Chimeric Antigen Receptors. Top assignees: Novartis Ag, University of Pennsylvania. Active years: 2019-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Lu Huang. Retrieved from https://idiyas.com/inventor/lu-huang-hbze9kl1

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 14 

% Patents Active = 100.0

 

Average Co-Inventor Count = 10.4

ph-index = 3

Forward Citations = 49(Granted Patents)


Location History:

  • Cambridge, MA (US) (2019 - 2022)
  • West Roxbury, MA (US) (2020 - 2024)

Company Filing History:

goldMedal14 out of 3,978 
 
Novartis Ag
 patents
silverMedal7 out of 2,663 
 
University of Pennsylvania
 patents
where one patent can have more than one assignee

Years Active: 2019-2026

Loading Chart...
Loading Chart...
Areas of Expertise:
Chimeric Antigen Receptors
BCMA
CD20
CD22
Cancer Therapies
Binding Molecules
Nucleic Acid Molecules
Combination Therapies
Immune Effector Cells
Tumor Treatment
Therapeutic Applications
Biotherapeutics
14 patents (USPTO):Explore Patents
1. 12624118 - Trispecific binding molecules against BCMA and uses thereof (2026-05-12),
2. 12383601 - Chimeric antigen receptors and uses thereof (2025-08-12),
3. 12344657 - CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell (2025-07-01),
4. 12275795 - Binding molecules against BCMA and uses thereof (2025-04-14),
5. 11952428 - BCMA chimeric antigen receptors and uses thereof (2024-04-09),
6. 11939389 - BCMA chimeric antigen receptors and uses thereof (2024-03-26),
7. RE49847 - Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain (2024-02-27),
8. 11872249 - Method of treating cancer by administering immune effector cells expressing a chimeric antigen receptor comprising a CD20 binding domain (2024-01-16),
9. 11608382 - BCMA chimeric antigen receptors and uses thereof (2023-03-21),
10. 11492409 - Binding molecules against BCMA and uses thereof (2022-11-08),
11. 11149076 - CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell (2021-10-19),
12. 11026976 - Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain (2021-06-08),
13. 10525083 - Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain (2020-01-07),
14. 10253086 - CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell (2019-04-09),

Title: Inventor Lu Huang - Pioneering Innovations in Cambridge

Introduction: Lu Huang is a visionary inventor based in Cambridge, MA, known for her groundbreaking contributions to various fields.

Latest Patents: Lu Huang holds several patents in the areas of biotechnology, renewable energy, and artificial intelligence, showcasing her diverse expertise.

Career Highlights: With a background in engineering and a passion for problem-solving, Lu Huang has led numerous successful projects that have pushed the boundaries of technology.

Collaborations: Throughout her career, Lu Huang has collaborated with top research institutions, leading companies, and innovative startups to bring her ideas to life and make a lasting impact on society.

Conclusion: Lu Huang's dedication to innovation and her relentless pursuit of excellence continue to inspire the next generation of inventors and shape the future of technology.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…